Reneo Pharmaceuticals reports Q3 EPS (57c), consensus (57c)

The company had $125.6M in cash, cash equivalents, and short-term investments as of September 30, 2023. “We are looking forward to sharing topline results of our pivotal STRIDE study in December,” said CEO GregoryFlesher. “In addition, we continue to be encouraged by the high participation rate in our STRIDE AHEAD open-label extension study, and are happy to announce enrollment of our first patient with PMM due to nuclear DNA defect in this ongoing trial. This is a very exciting time for the Reneo team and we want to thank our clinicians, patients, and stakeholders for supporting the mavodelpar development program.”